These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7851109)

  • 21. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
    Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
    Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.
    Pemberton LS; Din OS; Fisher PM; Hatton MQ
    Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):161-7. PubMed ID: 19111452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable).
    Rowell NP; Williams CJ
    Cochrane Database Syst Rev; 2001; (1):CD002935. PubMed ID: 11279780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee.
    Hopwood P; Harvey A; Davies J; Stephens RJ; Girling DJ; Gibson D; Parmar MK
    Eur J Cancer; 1998 Jan; 34(1):49-57. PubMed ID: 9624237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long term results of surgery versus continuous hyperfractionated accelerated radiotherapy (CHART) in patients aged >70 years with stage 1 non-small cell lung cancer.
    Ghosh S; Sujendran V; Alexiou C; Beggs L; Beggs D
    Eur J Cardiothorac Surg; 2003 Dec; 24(6):1002-7. PubMed ID: 14643820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperfractionation: where do we stand?
    Beck-Bornholdt HP; Dubben HH; Liertz-Petersen C; Willers H
    Radiother Oncol; 1997 Apr; 43(1):1-21. PubMed ID: 9165132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART).
    Jenkins P; D'Amico K; Benstead K; Elyan S
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):360-6. PubMed ID: 12738310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome.
    Bentzen SM; Saunders MI; Dische S
    Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):372-81. PubMed ID: 12555876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is control of the primary tumour worthwhile in non-oat cell carcinoma of the bronchus?
    Saunders MI
    Clin Oncol (R Coll Radiol); 1991 Jul; 3(4):185-8. PubMed ID: 1657111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic overview of radiation therapy effects in non-small cell lung cancer.
    Sirzén F; Kjellén E; Sörenson S; Cavallin-Ståhl E
    Acta Oncol; 2003; 42(5-6):493-515. PubMed ID: 14596509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial.
    Bentzen SM; Saunders MI; Dische S; Bond SJ
    Radiother Oncol; 2001 Aug; 60(2):123-35. PubMed ID: 11439207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fractionation and dose in thoracic radiotherapy.
    Saunders MI
    Lung Cancer; 1994 Mar; 10 Suppl 1():S245-52. PubMed ID: 8087516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review.
    Rowell NP; Williams CJ
    Thorax; 2001 Aug; 56(8):628-38. PubMed ID: 11462066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
    Baumann M; Herrmann T; Koch R; Matthiessen W; Appold S; Wahlers B; Kepka L; Marschke G; Feltl D; Fietkau R; Budach V; Dunst J; Dziadziuszko R; Krause M; Zips D;
    Radiother Oncol; 2011 Jul; 100(1):76-85. PubMed ID: 21757247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers.
    Dobrowsky W; Naudé J
    Radiother Oncol; 2000 Nov; 57(2):119-24. PubMed ID: 11054514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous hyperfractionated accelerated therapy in non-small-cell lung cancer.
    Würschmidt F; Heilmann HP
    Lancet; 1997 Sep; 350(9081):888. PubMed ID: 9310628
    [No Abstract]   [Full Text] [Related]  

  • 37. Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: a competing risks analysis.
    Ataman OU; Bentzen SM; Saunders MI; Dische S
    Br J Cancer; 2001 Oct; 85(8):1113-8. PubMed ID: 11710822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
    Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N
    Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small cell lung cancer.
    Catalano G; Piperno G; Orecchia R
    Radiother Oncol; 2010 May; 95(2):258; author reply 258-9. PubMed ID: 20347165
    [No Abstract]   [Full Text] [Related]  

  • 40. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer.
    Bentzen SM; Saunders MI; Dische S
    Radiother Oncol; 1999 Dec; 53(3):219-26. PubMed ID: 10660202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.